Acasti Pharma Q2 FY2023: net loss $4.9M; cash $34.9M; advances three clinical programs

Grace Therapeutics, Inc.

2022-Q2 EPS reported -$0.21

Net loss $4.9M ($0.11/sh) vs net income $1.0M in prior-year quarter; operating loss $5.1M.
R&D expenses rose to $3.3M from $0.6M due to PK studies for GTX-104, -102, -101.
Cash & short-term investments $34.9M as of Sep 30, 2022, down from $43.7M at Mar 31, 2022; runway through at least Mar 2024.
FDA Type C meeting on GTX-104 Phase 3 design expected by end of 2022/early Q1 2023; GTX-102 and GTX-101 PK topline results by end of 2022.
Vimal Kavuru appointed Chairman of the Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Grace Therapeutics, Inc. reported financial results for the second quarter ended September 30, 2022.

Period: the second quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.